Simona Halep to appeal four-year doping ban

Halep has claimed experts found she had accidentally taken a contaminated supplement.


Former world number one Simona Halep has been given a four-year ban from tennis for two doping offences, the International Tennis Integrity Agency has confirmed.

The 31-year-old Romanian has been provisionally suspended since October last year after testing positive for the blood-boosting substance Roxadustat at the 2022 US Open tournament.

And in May the two-time Grand Slam singles champion was charged with a second anti-doping breach relating to irregularities in her Athlete Biological Passport (ABP).

Both charges have been upheld by an independent tribunal.

Halep, who has been provisionally suspended since October 2022, will not be able to play professional tennis again until October 6 2026.

‘My fight continues’

But soon after the ITIA statement was released, Halep announced she would appeal the decision, saying: “Today (Tuesday), a tribunal under the tennis anti-doping programme announced a tentative decision in my case. The last year has been the hardest match of my life, and unfortunately my fight continues.

“I have devoted my life to the beautiful game of tennis, and I take the rules that govern our sport very seriously and take pride in the fact I have never knowingly or intentionally used any prohibited substance. I refused to accept their decision of a four-year ban and I intend to appeal to The Court of Arbitration for Sport.”

ALSO READ: Djokovic aims to ‘keep going’ in quest for more Grand Slam titles

A panel, which heard evidence from Halep, the winner of the 2018 French Open and 2019 Wimbledon singles titles, met in London on June 28-29.

On September 11, the panel — which also heard evidence from scientific experts and sifted through some 8,000 pages of evidence — confirmed it had found Halep had committed intentional violations under tennis’s anti-doping programme.

One of these was the use of Roxadustat discovered in her urine sample at the 2022 US Open, with the other breach based on collection and analysis of 51 blood samples provided by Halep as part of the ABP programme.

Claim of contamination

The ABP system is designed for the long-term monitoring of an athlete’s blood indicators with the aim of identifying irregularities that could indicate doping.

Halep has claimed experts found she had accidentally taken a contaminated supplement.

But the ITIA said Tuesday that while the tribunal accepted this claim, they also “determined the volume the player ingested could not have resulted in the concentration of Roxadustat found in the positive sample”.

ITIA chief executive Karen Moorhouse said: “After a complex and rigorous hearing process, we welcome the decision.”

She added: “The ITIA has followed the proper processes as we would with any other individual –- in accordance with the world anti-doping code –- fulfilling our purpose and responsibility to uphold the principle of fair competition, on behalf of the sport.

“The panel recognised that appropriate procedure had been followed within the written decision.”

Moorhouse said that, given “the significant public interest”, the full decision in Halep’s case “will be published in due course”.

Read more on these topics

doping Tennis

Access premium news and stories

Access to the top content, vouchers and other member only benefits